LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the appointment of Sarah Kalil as Chief Operating Officer and Steven Scampini as Vice President of Engineering. Ms. Kalil and Mr. Scampini were both most recently employed by Hologic, a leading manufacturer and supplier of diagnostic, surgical and medical imaging equipment and products. Kalil and Scampini each have significant expertise in key areas related to the Company’s anticipated commercialization of its flagship diagnostic test, T2Candida™, for the rapid and sensitive detection of species-specific Candida directly from a non-blood culture, whole blood specimen in approximately three hours with a limit of detection as low as 1 CFU/mL.
“Sarah and Steve bring to T2 Bio over 50 years of combined experience in the development and commercialization of medical devices and diagnostics – key skill sets that will strengthen T2 Bio’s leadership team as we prepare for the anticipated launch of T2Candida next year,” said John McDonough, President and CEO, T2 Biosystems. “We look forward to their contributions in realizing the potential value that this breakthrough diagnostic can have for patients and healthcare providers.”
“I am thrilled to be a part of T2 Biosystems’ innovative team as we bring this potentially life-saving product to patients with sepsis,” commented Sarah Kalil. “Importantly, we believe T2Candida could be the first of many breakthrough products powered by T2 Bio’s versatile T2MR® platform.”
Sarah Kalil brings to T2 Biosystems over 20 years of experience in the medical device industry. Prior to joining T2 Biosystems, Sarah was the COO of Interlace Medical. Interlace Medical was acquired by Hologic in January of 2011 and Sarah became part of Hologic Corporate Operations where she led the team responsible for the scale up of the MyoSure product line. Sarah’s previous experience includes roles of President of Boston Endo-Surgical Technologies, Advisor to Veniti Medical, Operations Director at INNOVEND and SleepNet Technologies and VP of QA/RA at American Surgical Technologies and Contraves. Sarah received her BS in engineering from the University of Vermont. She is a member of the Massachusetts General Hospital Cancer Patient and Family Advisory Council and a board member of the Pleiades Charitable Foundation.
“I believe that T2 Bio’s T2MR technology, which is a powerful platform for the rapid and sensitive detection of virtually any immunodiagnostic, molecular or hemostasis target, could be the foundation for a wide variety of novel diagnostic products,” stated Steve Scampini. “I look forward to exploring a range of diagnostic opportunities enabled by this game-changing technology with T2 Bio.”
Steve Scampini brings to T2 Biosystems over 35 years of experience in the medical device and diagnostics industries. Prior to joining T2 Biosystems, Steve served as a Senior Director of Product Development at Hologic, where he led the development of instrumentation for cervical cancer screening. Prior to joining Hologic, Steve served in numerous research and development roles at Philips Medical Systems, developing devices and products for ultrasonic imaging, patient resuscitation, cardiac magnetic resonance imaging, electrocardiography and medical image printing. Steve is named on a number of patents describing technological innovations related to medical devices and diagnostic instrumentation. Steve received his undergraduate degree from Rensselaer Polytechnic Institute and his master’s degree from California Institute of Technology, both in electrical engineering.
About T2 Biosystems
T2 Biosystems is developing a new class of clinical diagnostics powered by T2MR®, the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. T2 Bio’s pipeline of molecular diagnostic and hemostasis products is focused on conditions where rapid and accurate results will have the greatest impact on patients’ lives and healthcare costs. The Company’s lead products, T2Candida™ and T2Bacteria™, identify life-threatening pathogens associated with sepsis directly from whole blood up to 25-times faster than blood culture.
